JSW
ABBV icon

Journey Strategic Wealth’s AbbVie ABBV Stock Holding History

Journey Strategic Wealth’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$5.42M Buy
24,928
+1,849
+8% +$410K 0.13% 47
2025
Q4 		$5.27M Sell
23,079
-238
-1% -$54.2K 0.14% 47
2025
Q3 		$5.4M Buy
23,317
+265
+1% +$54K 0.15% 46
2025
Q2 		$4.28M Buy
23,052
+6,856
+42% +$1.27M 0.14% 55
2025
Q1 		$3.39M Buy
16,196
+6,469
+67% +$1.26M 0.12% 55
2024
Q4 		$1.73M Buy
9,727
+2,671
+38% +$491K 0.06% 83
2024
Q3 		$1.39M Buy
7,056
+808
+13% +$151K 0.05% 99
2024
Q2 		$1.07M Buy
6,248
+165
+3% +$27.3K 0.05% 85
2024
Q1 		$1.11M Buy
6,083
+3,956
+186% +$682K 0.05% 72
2023
Q4 		$330K Sell
2,127
-39
-2% -$5.69K 0.02% 127
2023
Q3 		$323K Sell
2,166
-368
-15% -$54K 0.02% 110
2023
Q2 		$341K Sell
2,534
-2,341
-48% -$343K 0.02% 108
2023
Q1 		$777K Sell
4,875
-774
-14% -$118K 0.08% 71
2022
Q4 		$913K Buy
5,649
+852
+18% +$131K 0.11% 61
2022
Q3 		$644K Buy
4,797
+1,718
+56% +$247K 0.09% 55
2022
Q2 		$472K Sell
3,079
-1,178
-28% -$180K 0.06% 61
2022
Q1 		$690K Buy
4,257
+210
+5% +$30.5K 0.08% 34
2021
Q4 		$548K Buy
+4,047
New +$478K 0.06% 66

Other funds holding ABBV

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Journey Strategic Wealth's ABBV Position: Q1 2026 in Review

Journey Strategic Wealth increased its AbbVie (ABBV) stake by 8% in Q1 2026, buying an estimated $410K and bringing the position to 24,928 shares worth $5.42M. The position accounts for 0.13% of the portfolio, ranked #47.

Journey Strategic Wealth first reported a position in ABBV in Q4 2021 and has held it in 18 quarters since. 4,077 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

  • Journey Strategic Wealth held 24,928 shares of AbbVie worth $5.42M as of Q1 2026.
  • Journey Strategic Wealth bought 1,849 AbbVie shares in Q1 2026, an estimated $410K.
  • AbbVie made up 0.13% of Journey Strategic Wealth's portfolio in Q1 2026, its #47 holding.
  • Journey Strategic Wealth first reported a position in AbbVie in Q4 2021 and has held it in 18 quarters since.
  • 4,077 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Journey Strategic Wealth's 13F filing for Q1 2026, filed 15 Apr 2026.